In NSCLC cells with initial EGFR-L858R mutation, the presence of secondary T790M mutation was found to affect the binding of gefitinib to mutated EGFR, with increased affinity of L858-T790M-EGFR to ATP when compared to L858 alone [30]. Here, EGFR is linked to non-small cell lung carcinoma.